سعر ماي فورتك 360مجم 120 قرص 2024

Myfortic mycophenolic acid 360 mg (as mycophenolate sodium) enteric-coated delayed-release tablets, pack of 120 (Novartis); immunosuppressant for prophylaxis of kidney transplant rejection.

• Prophylaxis of organ rejection in adults receiving a kidney transplant, in combination with ciclosporin and corticosteroids.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Prophylaxis of organ rejection in paediatric kidney transplant patients ≥5 years of age who are at least 6 months post-transplant, in combination with ciclosporin and corticosteroids.Population: Children ≥5 years, ≥6 months post-transplantDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (≥20%): anaemia, leukopenia, constipation, nausea, diarrhoea, vomiting, dyspepsia, urinary tract infection, CMV infection, insomnia and postoperative pain.International label, same product · DailyMed (U.S. National Library of Medicine)

• History of hypersensitivity, including anaphylaxis, to mycophenolate sodium, mycophenolic acid, mycophenolate mofetil or any excipient.International label, same product · DailyMed (U.S. National Library of Medicine)

• Boxed warning: use during pregnancy is associated with increased risks of pregnancy loss and congenital malformations; avoid if safer options exist and counsel females of reproductive potential on pregnancy prevention and planning. Only physicians experienced in immunosuppressive therapy and transplant management should prescribe it. Increased risk of lymphoma and other malignancies, particularly of the skin. Increased susceptibility to bacterial, viral, fungal and protozoal infections, including opportunistic infections.International label, same product · DailyMed (U.S. National Library of Medicine)
• Monitor for blood dyscrasias (neutropenia, pure red cell aplasia) and interrupt or reduce the dose if they occur; risk of serious GI complications (bleeding, ulceration, perforation); avoid in hereditary HGPRT deficiency; acute inflammatory syndrome and hypersensitivity reactions possible; avoid live attenuated vaccines; no blood donation during therapy and for 6 weeks after, no semen donation during therapy and for 90 days after.International label, same product · DailyMed (U.S. National Library of Medicine)

• Antacids with magnesium and aluminium hydroxidesDecrease MPA concentrations; concomitant use not recommended.DailyMed (U.S. National Library of Medicine)
• AzathioprineCompetition for purine metabolism; concomitant administration not recommended.DailyMed (U.S. National Library of Medicine)
• Cholestyramine, bile acid sequestrants, oral activated charcoalInterfere with enterohepatic recirculation and may decrease MPA concentrations; concomitant use not recommended.DailyMed (U.S. National Library of Medicine)

• After oral or IV dosing MMF is metabolised to MPA, the active moiety of Myfortic; MMF use in pregnancy is associated with increased first-trimester pregnancy loss and multiple congenital malformations in multiple organ systems; animal studies showed malformations and pregnancy loss below clinical exposure; discuss risks and benefits and consider alternative immunosuppressants with less embryofetal toxicity.International label, same product · DailyMed (U.S. National Library of Medicine)
• No data on mycophenolate in human milk; MPA is present in rat milk; only limited registry data on breastfed infants are available; potential infant risk cannot be excluded, so weigh breastfeeding benefits against the mother's need for therapy.International label, same product · DailyMed (U.S. National Library of Medicine)

• Mycophenolate sodium (mycophenolic acid 360 mg): Enteric formulation of mycophenolate sodium delivering mycophenolic acid (MPA), a selective uncompetitive IMPDH inhibitor that blocks de novo guanosine nucleotide synthesis in lymphocytes.